Washington University Rheumatic Diseases Research Resource-based Center

华盛顿大学风湿病研究资源中心

• 批准号: 10704273
• 负责人: Deborah J Lenschow
• 金额: $ 77.75万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10704273
• 关键词: Acceleration; Address; Adopted; Area; Autoimmunity; Basic Science; Biomedical Engineering; COVID-19 pandemic; Cell Line; Cell Therapy; Clinical; Clinical Data; Clinical Research; Collaborations; Collection; Complex; Core Facility; Cytometry; Data; Data Collection; Deposition; Discipline; Disease; Disease model; Education; Electronic Health Record; Environment; Evidence based program; Extramural Activities; Fostering; Funding; Genome engineering; Goals; Grant; Health; Image; Inflammation; Infrastructure; Knock-in; Knockout Mice; Laboratories; Lupus; Mentors; Microscopy; Modeling; Molecular Analysis; Pathogenesis; Pathway interactions; Patients; Phenotype; Philosophy; Physicians; Positioning Attribute; Postbaccalaureate; Regenerative Medicine; Reporting; Research; Research Personnel; Resources; Rheumatism; Rheumatology; Scientist; Services; Talents; Technology; Testing; Training; Translating; Translational Research; Universities; Washington; biobank; cellular imaging; cost effective; design; health care disparity; high dimensionality; improved; innovative technologies; interest; lupus registry; member; model building; multidisciplinary; multimodality; new technology; next generation; novel; novel therapeutic intervention; pre-clinical; precision medicine; programs; recruit; repository; response; social; social health determinants; transcriptomics

OVERALL ABSTRACT The WU-RDRRC seeks to advance the health of patients with rheumatic diseases by supporting enabling technology and promoting the members’ basic, clinical, and translational research interests that are organized around three major themes: 1) elucidating basic mechanisms of inflammation and autoimmunity; 2) accelerating clinical/translational research to inform precision medicine; and 3) advancing genome engineering and regenerative medicine to develop new treatment approaches for rheumatic diseases. We posit that translational research endeavors in rheumatic diseases require a team approach cultivated in a vibrant environment and supported by cross-disciplinary groups of experts and cutting-edge technologies. Over the past four years, this operational philosophy and the infrastructure supported by the WU-RDRRC perfectly positioned our investigators to increase the efficiency and impact of their research, allowed them to quickly address emergent issues that arose during the COVID-19 pandemic, and helped a number of young investigators obtain extramural funding and successfully transition to research independence. The WU- RDRRC propose to continue promoting rheumatic disease research by: 1) providing the infrastructure, education, and training needed to assist investigators with the experimental and scientific design of their projects; 2) organizing and supporting Core laboratories that will adopt and apply innovative technologies and expertise that would otherwise be unavailable to investigators in a cost-effective manner; 3) promoting interest in rheumatic diseases research by engaging multidisciplinary teams and bringing together diverse disciplines and clinical divisions to address roadblocks in translational science; 4) fostering the next generation of junior investigators who are interested in the study of rheumatic disease-related areas. To accomplish our goals we propose four cores: 1) a Biobank and Phenotyping Core to collect high-quality biospecimens for downstream molecular analysis; 2) a Genome Engineering Core to generate bioengineered cell-based therapies, knockin/knockout mice for testing in preclinical disease models; 3) a Cellular Imaging Core that offers novel microscopy technologies for building models of health and disease; and 4) an Administrative Core that promotes collaborative and synergistic interactions among rheumatic disease researchers and the mentoring of junior and new investigators interested in rheumatic disease research. In addition, we will address members’ evolving needs by expanding access to novel technologies such as spatial transcriptomics, and the changing societal landscape by incorporating social determinants of health into clinical data collection, and enhancing diversity of trainees entering the physician-scientist pathway.

总体摘要 WU-RDRRC 致力于通过支持促进风湿病患者的健康 技术并促进会员的基础、临床和转化研究兴趣 围绕三个主题：1）阐明炎症和自身免疫的基本机制；2） 加速临床/转化研究，为精准医学提供信息；3) 推进基因组工程 和再生医学开发风湿性疾病的新治疗方法。 我们认为，风湿病的转化研究工作需要培养团队合作精神 一个充满活力的环境，并得到跨学科专家组和尖端技术的支持。 过去四年来，这种运作理念和WU-RDRRC支持的基础设施 我们的研究人员处于完美的位置，可以提高研究的效率和影响力，使他们能够 迅速解决在 COVID-19 大流行期间出现的紧急问题，并帮助了许多年轻人 研究人员获得校外资助并成功过渡到研究独立性。 RDRRC 建议通过以下方式继续促进风湿病研究：1）提供基础设施， 协助研究人员进行实验和科学设计所需的教育和培训 2）组织和支持采用和应用创新技术的核心实验室； 3) 提高研究者的兴趣； 通过参与多学科团队并将不同学科结合起来进行风湿病研究 和临床部门，以解决转化科学中的障碍；4）培养下一代初级人才； 对风湿病相关领域的研究感兴趣的研究人员。 为了实现我们的目标，我们提出了四个核心：1）生物库和表型分析核心来收集高质量的 用于下游分子分析的生物样本；2) 用于生成生物工程的基因组工程核心； 基于细胞的疗法，用于临床前疾病模型测试的敲入/敲除小鼠；3) 细胞成像； 提供用于构建健康和疾病模型的新型显微镜技术的核心；4) 促进风湿病之间协作和协同相互作用的管理核心 研究人员以及对风湿病研究感兴趣的初级和新研究人员的指导。 此外，我们将通过扩大新技术的使用范围来满足会员不断变化的需求，例如 空间转录组学，以及通过将健康的社会决定因素纳入不断变化的社会景观 临床数据收集，并提高进入医师-科学家途径的学员的多样性。

项目成果

Caspase-1-driven neutrophil pyroptosis and its role in host susceptibility to Pseudomonas aeruginosa.

Caspase-1 驱动的中性粒细胞焦亡及其在宿主对铜绿假单胞菌易感性中的作用。

• 发表时间: 2022-07
• 影响因子: 6.7
• 作者: Santoni, Karin;Pericat, David;Gorse, Leana;Buyck, Julien;Pinilla, Miriam;Prouvensier, Laure;Bagayoko, Salimata;Hessel, Audrey;Leon;Bellard, Elisabeth;Mazères, Serge;Doz;Winter, Nathalie;Paget, Christophe
• 通讯作者: Paget, Christophe

Listeria motility increases the efficiency of epithelial invasion during intestinal infection.

李斯特菌的运动增加了肠道感染期间上皮细胞入侵的效率。

• 发表时间: 2022-12
• 影响因子: 6.7
• 作者: Wortel, Inge M N;Kim, Seonyoung;Liu, Annie Y;Ibarra, Enid C;Miller, Mark J
• 通讯作者: Miller, Mark J

Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.

COVID-19 大流行期间羟氯喹和氯喹的使用：每位临床医生都应该了解的内容。

• 发表时间: 2020
• 影响因子: 39.2
• 作者: Yazdany, Jinoos;Kim, Alfred H J
• 通讯作者: Kim, Alfred H J

Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre et al.

回应：“COVID-19 和风湿病患者的抗疟药使用和心律失常：剂量和炎症问题？”

• 发表时间: 2021
• 影响因子: 27.4
• 作者: Graef, Elizabeth R;Liew, Jean W;Kim, Alfred Hj;Sparks, Jeffrey A
• 通讯作者: Sparks, Jeffrey A

Anti-JNK2 peptide-siRNA nanostructures improve plaque endothelium and reduce thrombotic risk in atherosclerotic mice.

抗 JNK2 肽-siRNA 纳米结构可改善动脉粥样硬化小鼠的斑块内皮并降低血栓形成风险。

• 发表时间: 2018
• 作者: Pan, Hua;Palekar, Rohun U;Hou, Kirk K;Bacon, John;Yan, Huimin;Springer, Luke E;Akk, Antonina;Yang, Lihua;Miller, Mark J;Pham, Christine Tn;Schlesinger, Paul H;Wickline, Samuel A
• 通讯作者: Wickline, Samuel A